Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation NIHR HSRIC. Abiraterone (Zytiga) for hormone-naïve metastatic prostate cancer – first line. Birmingham: NIHR Horizon Scanning Research&Intelligence Centre. Horizon Scanning Review. 2015 Authors' objectives Prostate cancer is usually a slowly growing cancer and may never cause any problems in some men. However, most men need treatment once it has spread to other parts of the body.
Abiraterone is a new drug for the treatment of prostate cancer for patients who have not yet received any other treatment. It is given as a tablet taken once daily. Some studies have suggested that abiraterone may work best in combination with two drugs that are already used for the treatment of prostate cancer, prednisolone and androgen deprivation therapy.
If abiraterone is licensed for use in the UK, it could be a new treatment option that may improve survival and the quality of life of men with prostate cancer. Indexing Status Subject indexing assigned by CRD MeSH Abiraterone Acetate; Androstenes; Androstenols; Humans; Male; Prostatic Neoplasms Language Published English Country of organisation England English summary An English language summary is available. Address for correspondence NIHR Horizon Scanning Research&Intelligence Centre, University of Birmingham, Institute of Applied Health Research, Public Health building, Edgbaston, Birmingham B15 2TT
Tel: 0121 414 9077 Email: nihrhsc@contacts.bham.ac.uk AccessionNumber 32016000393 Date abstract record published 04/03/2016 |